Inventiva reports preliminary 2025¹ fiscal year financial results

Core Viewpoint - Inventiva reported preliminary unaudited financial results for the full year ending December 31, 2025, highlighting significant changes in cash flow, revenues, and operational expenses as it continues to focus on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1]. Financial Position - As of December 31, 2025, the company's cash and cash equivalents were €99.3 million, with short-term deposits amounting to €131.6 million, an increase from €96.6 million in cash and cash equivalents in 2024 [2]. - The company estimates that its cash resources will support operations until the middle of the first quarter of 2027, potentially extending to the middle of the third quarter of 2027 with additional proceeds from the exercise of warrants [7]. Cash Flow Analysis - Net cash used in operating activities was (€104.6) million in 2025, a 22% increase from (€85.9) million in 2024, primarily due to a strategic pipeline prioritization plan and lower revenues from licensing agreements [3]. - Net cash used in investing activities was (€133.2) million in 2025, significantly higher than €8.7 million generated in 2024, mainly due to new short-term deposits [4]. - Net cash generated from financing activities was €241.1 million in 2025, up from €145.6 million in 2024, driven by proceeds from structured financing and a public offering in the United States [5]. Revenue Performance - The company's revenues for 2025 were €4.5 million, a decrease from €9.2 million in 2024, primarily consisting of milestone payments and credit notes from licensing agreements [8]. Future Financial Reporting - The company plans to publish its audited financial results for the full fiscal year 2025 on March 30, 2026, after the U.S. market close [9]. Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for MASH, currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [10].